Instituto de Biomedicina de Valencia (IBV-CSIC), Valencia, Spain.
Group 739, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) - Instituto de Salud Carlos III, Valencia, Spain.
Protein Sci. 2021 Oct;30(10):1995-2008. doi: 10.1002/pro.4158. Epub 2021 Jul 22.
CAD is a 1.5 MDa particle formed by hexameric association of a 250 kDa protein divided into different enzymatic domains, each catalyzing one of the initial reactions for de novo biosynthesis of pyrimidine nucleotides: glutaminase-dependent Carbamoyl phosphate synthetase, Aspartate transcarbamoylase, and Dihydroorotase. The pathway for de novo pyrimidine synthesis is essential for cell proliferation and is conserved in all living organisms, but the covalent linkage of the first enzymatic activities into a multienzymatic CAD particle is unique to animals. In other organisms, these enzymatic activities are encoded as monofunctional proteins for which there is abundant structural and biochemical information. However, the knowledge about CAD is scarce and fragmented. Understanding CAD requires not only to determine the three-dimensional structures and define the catalytic and regulatory mechanisms of the different enzymatic domains, but also to comprehend how these domains entangle and work in a coordinated and regulated manner. This review summarizes significant progress over the past 10 years toward the characterization of CAD's architecture, function, regulatory mechanisms, and cellular compartmentalization, as well as the recent finding of a new and rare neurometabolic disorder caused by defects in CAD activities.
CAD 是由 250kDa 蛋白六聚体组成的 1.5MDa 颗粒,该蛋白分为不同的酶结构域,每个结构域催化从头合成嘧啶核苷酸的初始反应之一:谷氨酰胺酶依赖性氨基甲酰磷酸合成酶、天冬氨酸转氨甲酰酶和二氢乳清酸酶。从头嘧啶合成途径对于细胞增殖是必需的,并且存在于所有生物中,但将最初的酶活性共价连接到多酶 CAD 颗粒中是动物所特有的。在其他生物体中,这些酶活性被编码为单功能蛋白,这些蛋白具有丰富的结构和生化信息。然而,关于 CAD 的知识却很少且分散。理解 CAD 需要不仅确定不同酶结构域的三维结构和定义其催化和调节机制,还要理解这些结构域如何以协调和调节的方式纠缠和工作。这篇综述总结了过去 10 年在 CAD 结构、功能、调节机制和细胞区室化方面的重要进展,以及最近发现的一种由 CAD 活性缺陷引起的新的罕见神经代谢疾病。